Dose escalation randomised study of efmarodocokin alfa in healthy volunteers and patients with ulcerative colitis

Conclusion
Efmarodocokin alfa had an adequate safety and pharmacokinetic profile in HVs and patients. Biomarker data confirmed IL-22R pathway activation in the colonic epithelium. Results support further investigation of this non-immunosuppressive potential inflammatory bowel disease therapeutic.

Trial registration number
NCT02749630.

Source: Gut - July 6, 2023 Category: Gastroenterology Authors: Wagner, F., Mansfield, J. C., Lekkerkerker, A. N., Wang, Y., Keir, M., Dash, A., Butcher, B., Harder, B., Orozco, L. D., Mar, J. S., Chen, H., Rothenberg, M. E. Tags: Open access, Gut Inflammatory bowel disease Source Type: research